Apart from ibrutinib, individuals with M-CLL, devoid of TP53 aberrations and healthy adequate to tolerate FCR therapy, should be very good candidates with the latter, with the profit being this therapy might be completed in 6 months whilst ibrutinib need to be taken indefinitely. This feature will be especially valuable for non-compliant individual… Read More